重大事件
即時報告
8-K
2026-05-14
Gyre Therapeutics 將於2026年
AI 繁中摘要
Gyre Therapeutics 提交 8-K 申報，披露將於 2026 年 5 月 15 日在上海舉行的科學研討會上發表最新簡報 🧬。該簡報（附件 99.1）重點介紹公司的研發進展，但暫未提供具體財務數據或業績指引。管理層並未在文件中對未來表現作出展望。
是次披露屬 Regulation FD 下的自願性公開，旨在讓投資者同步了解公司於亞洲學術會議上的科學成果。對於持有 GYRE 股份的投資者而言，這份簡報或會提供關於臨床項目或技術平台的新亮點，但短期內股價波動主要取決於市場對簡報內容的解讀。建議留意即將公佈的完整簡報，以評估其對公司價值的潛在影響。
展開英文正文
false0001124105NASDAQ00011241052026-05-142026-05-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 14, 2026 Gyre Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 000-51173 56-2020050 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 12730 High Bluff Drive Suite 250 San Diego, CA 92130 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (858) 284-0115 N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock GYRE The Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 7.01 Regulation FD Disclosure. On May 15, 2026, Gyre Therapeutics, Inc. will be presenting the attached presentation at a scientific conference in Shanghai, China. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The exhibit furnished under Item 7.01 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing. Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 99.1 Presentation, dated May 2026 104 Cover page interactive data file (embedded within the inline XBRL document) 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GYRE THERAPEUTICS, INC. Date: May 14, 2026 By: /s/ Thomas Eastling Name: Thomas Eastling Title: Chief Financial Officer 3